| Literature DB >> 30447922 |
Antonio Chiappa1, Bruno Andreoni2, Renzo Dionigi3, Lorenzo Spaggiari4, Diego Foschi5, Gianluca Polvani6, Roberto Orecchia7, Nicola Fazio8, Gabriella Pravettoni9, Maria Laura Cossu10, Domenico Galetta4, Marco Venturino11, Carlo Ferrari12, Lorenzo Macone12, Cristiano Crosta13, Bernardo Bonanni14, Roberto Biffi15.
Abstract
Cancer of the esophagus and of gastroesophageal junction can be cured, even if with lacking cure rate. Different approaches have been developed, mostly when carcinoma has loco-regional pattern. Multimodality therapy showed a survival rate superior than 10% if compared to a single approach. This is a systematic review, carried to assess the following matters: Which therapeutic opportunities are available? Who could benefit of them? Which adverse reactions could possibly verify? How can physicians definitely choose the proper strategy? Which is the role of surgery? We mean to give either General Practitioner or specialists clear and efficient updates about current treatment of this tumour, starting from physical examination. Four eminent guidelines were consulted for our study: Cancer Care Ontario's Program in Evidence-Based Care, NCCN, Belgian Health Care Knowledge Centre and Esmo.Entities:
Keywords: Esophageal Cancer; Gastroesophageal junction cancer; Multimodal therapy; Surgical oncology
Mesh:
Year: 2018 PMID: 30447922 DOI: 10.1016/j.critrevonc.2018.10.002
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN: 1040-8428 Impact factor: 6.312